Osilodrostat, an oral cortisol synthesis inhibitor, was previously approved for treating adults with Cushing disease, a subtype of Cushing syndrome in which the hypercortisolemia is due to pituitary ...

The FDA has approved Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has not been curative.

The Food and Drug Administration (FDA) has approved Isturisa ® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option ...

Dan Ives reiterated that, despite the uncertainty created by tariffs, the demand for software remained a safety blanket, and ...

Clinicians who are unaware of the pseudocondition may mistake elevated cortisol results for signs of true Cushing syndrome ...

We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take ...

Cushing’s syndrome survivor and public health advocate, Ms. Aisha Adamu Fari, has urged the Federal Government to prioritize research, awareness, and early diagnosis of rare diseases in Nigeria.

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

On CORT's first-quarter 2025 earnings call, investors are likely to focus on the sales performance of its Cushing's syndrome drug, Korlym.

Angela Goodrich, 45, was shocked to be diagnosed with an extremely rare cancer. She shared her story and symptoms with TODAY ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...